J&J submits US filings for paliperidone palmitate and Invega
This article was originally published in Scrip
Johnson & Johnsonhas submitted the data requested by the US FDA in its complete response letter for paliperidone palmitate – a once-monthly injectable version of its daily oral atypical antipsychotic Invega – for the acute and maintenance treatment of schizophrenia.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.